Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	Free PDFs: Hepatology 2013 (574 pages) – Hepatitis C 2013 Amedeo Smart: the Smartphone Edition	Free Abstracts

Malignant Melanoma

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 45 articles: HTML format Text format

Single Articles

June 2013
1. WHEELER BW , Kothencz G, Pollard AS
   Geography of non-melanoma skin cancer and ecological associations with environmental risk factors in England.
   Br J Cancer. 2013 Jun 11. doi: 10.1038/bjc.2013.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   May 2013
2. GRANN AF , Froslev T, Olesen AB, Schmidt H, et al
   The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987-2009: a registry-based cohort study.
   Br J Cancer. 2013 May 16. doi: 10.1038/bjc.2013.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. BOECKE A , Carstens AC, Neacsu CD, Baschuk N, et al
   TNF-receptor-1 adaptor protein FAN mediates TNF-induced B16 melanoma motility and invasion.
   Br J Cancer. 2013 May 14. doi: 10.1038/bjc.2013.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. MILLWARD M , Underhill C, Lobb S, McBurnie J, et al
   Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.
   Br J Cancer. 2013 May 7. doi: 10.1038/bjc.2013.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   April 2013
5. HEINZERLING L , Kuhnapfel S, Meckbach D, Baiter M, et al
   Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.
   Br J Cancer. 2013 Apr 11. doi: 10.1038/bjc.2013.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   March 2013
6. O'BOYLE G , Swidenbank I, Marshall H, Barker CE, et al
   Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.
   Br J Cancer. 2013 Mar 28. doi: 10.1038/bjc.2013.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. EL HAJJ P , Journe F, Wiedig M, Laios I, et al
   Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients.
   Br J Cancer. 2013 Mar 21. doi: 10.1038/bjc.2013.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. KURIHARA M , Kirita T, Sasahira T, Ohmori H, et al
   Protumoral roles of melanoma inhibitory activity 2 in oral squamous cell carcinoma.
   Br J Cancer. 2013 Mar 19. doi: 10.1038/bjc.2013.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   February 2013
9. WILMOTT JS , Menzies AM, Haydu LE, Capper D, et al
   BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
   Br J Cancer. 2013 Feb 12. doi: 10.1038/bjc.2013.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2012
10. ALI Z , Fisher R, Larkin J
    Targeted therapeutics in melanoma.
    Br J Cancer. 2012;107:1663.
    PubMed     Text format     Related articles   
    
    
    
    September 2012
11. GIRARD E , Strathdee C, Trueblood E, Queva C, et al
    Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model.
    Br J Cancer. 2012 Sep 6. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2012
12. SEGUIN F , Carvalho MA, Bastos DC, Agostini M, et al
    The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.
    Br J Cancer. 2012 Aug 14. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2012
13. KRUIJFF S , Bastiaannet E, Francken AB, Schaapveld M, et al
    Breslow thickness in the Netherlands: a population-based study of 40 880 patients comparing young and elderly patients.
    Br J Cancer. 2012;107:570-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. WEIDE B , Elsasser M, Buttner P, Pflugfelder A, et al
    Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
    Br J Cancer. 2012 Jul 10. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. PECUCHET N , Lebbe C, Mir O, Billemont B, et al
    Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
    Br J Cancer. 2012 Jul 5. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2012
16. FEUN LG , Marini A, Walker G, Elgart G, et al
    Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
    Br J Cancer. 2012 Apr 3. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2012
17. WANG H , Lee S, Nigro CL, Lattanzio L, et al
    NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.
    Br J Cancer. 2012 Mar 27. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. HENARE K , Wang L, Wang LC, Thomsen L, et al
    Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.
    Br J Cancer. 2012;106:1134-47.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. YAMAMOTO K , Ohga N, Hida Y, Maishi N, et al
    Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells.
    Br J Cancer. 2012;106:1214-23.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2012
20. THOMAS S , Putter C, Weber S, Bornfeld N, et al
    Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study.
    Br J Cancer. 2012 Feb 21. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2012
21. WALDMANN A , Nolte S, Weinstock MA, Breitbart EW, et al
    Skin cancer screening participation and impact on melanoma incidence in Germany - an observational study on incidence trends in regions with and without population-based screening.
    Br J Cancer. 2012 Jan 31. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. SAKAIZAWA K , Goto Y, Kiniwa Y, Uchiyama A, et al
    Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.
    Br J Cancer. 2012 Jan 26. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. XU Y , Brenn T, Brown ER, Doherty V, et al
    Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.
    Br J Cancer. 2012 Jan 5. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2011
24. PARKIN DM , Mesher D, Sasieni P
    13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010.
    Br J Cancer. 2011;105 Suppl 2:S66-9.
    PubMed     Text format     Related articles   
    
    
    
    November 2011
25. ALGAZI AP , Weber JS, Andrews SC, Urbas P, et al
    Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
    Br J Cancer. 2011 Nov 29. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. JANJETOVIC Z , Brozyna AA, Tuckey RC, Kim TK, et al
    High basal NF-kappaB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives.
    Br J Cancer. 2011 Nov 17. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. JOURNE F , Boufker HI, Van Kempen L, Galibert MD, et al
    TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.
    Br J Cancer. 2011 Nov 1. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
28. KEIDAR M , Walk R, Shashurin A, Srinivasan P, et al
    Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy.
    Br J Cancer. 2011;105:1295-301.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. JOHNSON KJ , Carozza SE, Chow EJ, Fox EE, et al
    Birth characteristics and childhood carcinomas.
    Br J Cancer. 2011;105:1396-401.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. FUKUDA H , Mochizuki S, Abe H, Okano HJ, et al
    Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production.
    Br J Cancer. 2011 Oct 20. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
31. GRIGNOL V , Fairchild ET, Zimmerer JM, Lesinski GB, et al
    miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions.
    Br J Cancer. 2011;105:1023-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. WEST EJ , Scott KJ, Jennings VA, Melcher AA, et al
    Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.
    Br J Cancer. 2011;105:787-95.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
33. DE LUCA A , Lamura L, Strizzi L, Roma C, et al
    Expression and functional role of CRIPTO-1 in cutaneous melanoma.
    Br J Cancer. 2011 Aug 23. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. TAWBI HA , Villaruz L, Tarhini A, Moschos S, et al
    Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
    Br J Cancer. 2011 Aug 2. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
35. O'DAY S , Pavlick A, Loquai C, Lawson D, et al
    A randomised, phase II study of intetumumab, an anti-alpha(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma.
    Br J Cancer. 2011 Jul 12. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. EISEN T , Marais R, Affolter A, Lorigan P, et al
    Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
    Br J Cancer. 2011 Jul 12. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. GREMEL G , Ryan D, Rafferty M, Lanigan F, et al
    Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma.
    Br J Cancer. 2011 Jul 5. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
38. SIGALOTTI L , Fratta E, Parisi G, Coral S, et al
    Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
    Br J Cancer. 2011 Jun 21. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles   
    
    
    
    
39. BRAIG S , Wallner S, Junglas B, Fuchshofer R, et al
    CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration.
    Br J Cancer. 2011 Jun 14. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. DEBLACAM C , Byrne C, Hughes E, McIlroy M, et al
    HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.
    Br J Cancer. 2011 Jun 7. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
41. CHIARION-SILENI V , Guida M, Ridolfi L, Romanini A, et al
    Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
42. REUSCHENBACH M , Tran T, Faulstich F, Hartschuh W, et al
    High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. KHAN OA , Gore M, Lorigan P, Stone J, et al
    A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
    Br J Cancer. 2011;104:750-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. KUROSU T , Ohga N, Hida Y, Maishi N, et al
    HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium.
    Br J Cancer. 2011;104:819-29.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
45. WANG Y , Wang XY, Subjeck JR, Shrikant PA, et al
    Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
    Br J Cancer. 2011;104:643-52.
    PubMed     Text format     Related articles   
    
    
    

Thank you for your interest in scientific medicine.

This service is provided by AMEDEO through a media sponsorship by Boehringer Ingelheim.

All AMEDEO services are free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Amedeo is a Flying Publisher website.    Design: